The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neuroblastoma Chemotherapy Drugs Market Research Report 2024
Synopsis
Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.
Due to the COVID-19 pandemic, the global Neuroblastoma Chemotherapy Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Neuroblastoma Chemotherapy Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Neuroblastoma Chemotherapy Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Cyclophosphamide accounting for % of the Neuroblastoma Chemotherapy Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Neuroblastoma Chemotherapy Drugs include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi and Accord Healthcare and etc. In terms of revenue, the global 3 largest players have a % market share of Neuroblastoma Chemotherapy Drugs in 2021.
This report focuses on Neuroblastoma Chemotherapy Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Neuroblastoma Chemotherapy Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Neuroblastoma Chemotherapy Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Cyclophosphamide
Cisplatin or Carboplatin
Vincristine
Doxorubicin (Adriamycin)
Etoposide
Other
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Baxter Healthcare
Ingenus Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceuticals
Qilu Pharmaceutical
Pfizer
Hikma Pharmaceuticals
Fresenius Kabi
Accord Healthcare
Viatris
Chemotherapy (chemo) is the use of anti-cancer drugs, which are usually given into a vein. The drugs enter the bloodstream and travel throughout the body to reach and destroy cancer cells. This makes chemo useful for treating neuroblastoma, especially if it can't all be removed with surgery. The most common combination of drugs includes cisplatin (or carboplatin), cyclophosphamide, doxorubicin, vincristine, and etoposide, but others may be used.
Due to the COVID-19 pandemic, the global Neuroblastoma Chemotherapy Drugs market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Neuroblastoma Chemotherapy Drugs market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Neuroblastoma Chemotherapy Drugs landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Cyclophosphamide accounting for % of the Neuroblastoma Chemotherapy Drugs global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Neuroblastoma Chemotherapy Drugs include Baxter Healthcare, Ingenus Pharmaceuticals, ANI Pharmaceuticals, Teva Pharmaceuticals, Qilu Pharmaceutical, Pfizer, Hikma Pharmaceuticals, Fresenius Kabi and Accord Healthcare and etc. In terms of revenue, the global 3 largest players have a % market share of Neuroblastoma Chemotherapy Drugs in 2021.
This report focuses on Neuroblastoma Chemotherapy Drugs volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Neuroblastoma Chemotherapy Drugs market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Neuroblastoma Chemotherapy Drugs Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Cyclophosphamide
Cisplatin or Carboplatin
Vincristine
Doxorubicin (Adriamycin)
Etoposide
Other
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Baxter Healthcare
Ingenus Pharmaceuticals
ANI Pharmaceuticals
Teva Pharmaceuticals
Qilu Pharmaceutical
Pfizer
Hikma Pharmaceuticals
Fresenius Kabi
Accord Healthcare
Viatris
Index1 Neuroblastoma Chemotherapy Drugs Market Overview
1.1 Product Overview and Scope of Neuroblastoma Chemotherapy Drugs
1.2 Neuroblastoma Chemotherapy Drugs Segment by Type
1.2.1 Global Neuroblastoma Chemotherapy Drugs Sales Growth Rate Comparison by Type (2022-2028)
1.2.2 Cyclophosphamide
1.2.3 Cisplatin or Carboplatin
1.2.4 Vincristine
1.2.5 Doxorubicin (Adriamycin)
1.2.6 Etoposide
1.2.7 Other
1.3 Neuroblastoma Chemotherapy Drugs Segment by Application
1.3.1 Global Neuroblastoma Chemotherapy Drugs Sales Comparison by Application: (2022-2028)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Global Neuroblastoma Chemotherapy Drugs Market Size Estimates and Forecasts
1.4.1 Global Neuroblastoma Chemotherapy Drugs Revenue 2017-2028
1.4.2 Global Neuroblastoma Chemotherapy Drugs Sales 2017-2028
1.4.3 Neuroblastoma Chemotherapy Drugs Market Size by Region: 2017 Versus 2021 Versus 2028
2 Neuroblastoma Chemotherapy Drugs Market Competition by Manufacturers
2.1 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Manufacturers (2017-2022)
2.2 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Manufacturers (2017-2022)
2.3 Global Neuroblastoma Chemotherapy Drugs Average Price by Manufacturers (2017-2022)
2.4 Manufacturers Neuroblastoma Chemotherapy Drugs Manufacturing Sites, Area Served, Product Type
2.5 Neuroblastoma Chemotherapy Drugs Market Competitive Situation and Trends
2.5.1 Neuroblastoma Chemotherapy Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Neuroblastoma Chemotherapy Drugs Players Market Share by Revenue
2.5.3 Global Neuroblastoma Chemotherapy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neuroblastoma Chemotherapy Drugs Retrospective Market Scenario by Region
3.1 Global Neuroblastoma Chemotherapy Drugs Retrospective Market Scenario in Sales by Region: 2017-2022
3.2 Global Neuroblastoma Chemotherapy Drugs Retrospective Market Scenario in Revenue by Region: 2017-2022
3.3 North America Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country
3.3.1 North America Neuroblastoma Chemotherapy Drugs Sales by Country
3.3.2 North America Neuroblastoma Chemotherapy Drugs Revenue by Country
3.3.3 United States
3.3.4 Canada
3.4 Europe Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country
3.4.1 Europe Neuroblastoma Chemotherapy Drugs Sales by Country
3.4.2 Europe Neuroblastoma Chemotherapy Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Neuroblastoma Chemotherapy Drugs Sales by Region
3.5.2 Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 China Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.6 Latin America Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country
3.6.1 Latin America Neuroblastoma Chemotherapy Drugs Sales by Country
3.6.2 Latin America Neuroblastoma Chemotherapy Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.6.6 Colombia
3.7 Middle East and Africa Neuroblastoma Chemotherapy Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Neuroblastoma Chemotherapy Drugs Sales by Country
3.7.2 Middle East and Africa Neuroblastoma Chemotherapy Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Neuroblastoma Chemotherapy Drugs Historic Market Analysis by Type
4.1 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2022)
4.2 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Type (2017-2022)
4.3 Global Neuroblastoma Chemotherapy Drugs Price by Type (2017-2022)
5 Global Neuroblastoma Chemotherapy Drugs Historic Market Analysis by Application
5.1 Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2022)
5.2 Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Application (2017-2022)
5.3 Global Neuroblastoma Chemotherapy Drugs Price by Application (2017-2022)
6 Key Companies Profiled
6.1 Baxter Healthcare
6.1.1 Baxter Healthcare Corporation Information
6.1.2 Baxter Healthcare Description and Business Overview
6.1.3 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.1.4 Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolio
6.1.5 Baxter Healthcare Recent Developments/Updates
6.2 Ingenus Pharmaceuticals
6.2.1 Ingenus Pharmaceuticals Corporation Information
6.2.2 Ingenus Pharmaceuticals Description and Business Overview
6.2.3 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.2.4 Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio
6.2.5 Ingenus Pharmaceuticals Recent Developments/Updates
6.3 ANI Pharmaceuticals
6.3.1 ANI Pharmaceuticals Corporation Information
6.3.2 ANI Pharmaceuticals Description and Business Overview
6.3.3 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.3.4 ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio
6.3.5 ANI Pharmaceuticals Recent Developments/Updates
6.4 Teva Pharmaceuticals
6.4.1 Teva Pharmaceuticals Corporation Information
6.4.2 Teva Pharmaceuticals Description and Business Overview
6.4.3 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio
6.4.5 Teva Pharmaceuticals Recent Developments/Updates
6.5 Qilu Pharmaceutical
6.5.1 Qilu Pharmaceutical Corporation Information
6.5.2 Qilu Pharmaceutical Description and Business Overview
6.5.3 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.5.4 Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product Portfolio
6.5.5 Qilu Pharmaceutical Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.6.4 Pfizer Neuroblastoma Chemotherapy Drugs Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Hikma Pharmaceuticals
6.6.1 Hikma Pharmaceuticals Corporation Information
6.6.2 Hikma Pharmaceuticals Description and Business Overview
6.6.3 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.4.4 Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product Portfolio
6.7.5 Hikma Pharmaceuticals Recent Developments/Updates
6.8 Fresenius Kabi
6.8.1 Fresenius Kabi Corporation Information
6.8.2 Fresenius Kabi Description and Business Overview
6.8.3 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.8.4 Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product Portfolio
6.8.5 Fresenius Kabi Recent Developments/Updates
6.9 Accord Healthcare
6.9.1 Accord Healthcare Corporation Information
6.9.2 Accord Healthcare Description and Business Overview
6.9.3 Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.9.4 Accord Healthcare Neuroblastoma Chemotherapy Drugs Product Portfolio
6.9.5 Accord Healthcare Recent Developments/Updates
6.10 Viatris
6.10.1 Viatris Corporation Information
6.10.2 Viatris Description and Business Overview
6.10.3 Viatris Neuroblastoma Chemotherapy Drugs Sales, Revenue and Gross Margin (2017-2022)
6.10.4 Viatris Neuroblastoma Chemotherapy Drugs Product Portfolio
6.10.5 Viatris Recent Developments/Updates
7 Neuroblastoma Chemotherapy Drugs Manufacturing Cost Analysis
7.1 Neuroblastoma Chemotherapy Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Neuroblastoma Chemotherapy Drugs
7.4 Neuroblastoma Chemotherapy Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Neuroblastoma Chemotherapy Drugs Distributors List
8.3 Neuroblastoma Chemotherapy Drugs Customers
9 Neuroblastoma Chemotherapy Drugs Market Dynamics
9.1 Neuroblastoma Chemotherapy Drugs Industry Trends
9.2 Neuroblastoma Chemotherapy Drugs Market Drivers
9.3 Neuroblastoma Chemotherapy Drugs Market Challenges
9.4 Neuroblastoma Chemotherapy Drugs Market Restraints
10 Global Market Forecast
10.1 Neuroblastoma Chemotherapy Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Neuroblastoma Chemotherapy Drugs by Type (2023-2028)
10.1.2 Global Forecasted Revenue of Neuroblastoma Chemotherapy Drugs by Type (2023-2028)
10.2 Neuroblastoma Chemotherapy Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Neuroblastoma Chemotherapy Drugs by Application (2023-2028)
10.2.2 Global Forecasted Revenue of Neuroblastoma Chemotherapy Drugs by Application (2023-2028)
10.3 Neuroblastoma Chemotherapy Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Neuroblastoma Chemotherapy Drugs by Region (2023-2028)
10.3.2 Global Forecasted Revenue of Neuroblastoma Chemotherapy Drugs by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global Neuroblastoma Chemotherapy Drugs Sales Growth Rate Comparison by Type (2022-2028) & (K Units) & (US$ Million)
Table 2. Global Neuroblastoma Chemotherapy Drugs Sales Growth Rate Comparison by Application (2022-2028) & (K Units) & (US$ Million)
Table 3. Global Neuroblastoma Chemotherapy Drugs Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
Table 4. Global Neuroblastoma Chemotherapy Drugs Market Competitive Situation by Manufacturers in 2021
Table 5. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) of Key Manufacturers (2017-2022)
Table 6. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Manufacturers (2017-2022)
Table 7. Global Neuroblastoma Chemotherapy Drugs Revenue (US$ Million) by Manufacturers (2017-2022)
Table 8. Global Neuroblastoma Chemotherapy Drugs Revenue Share by Manufacturers (2017-2022)
Table 9. Global Market Neuroblastoma Chemotherapy Drugs Average Price (US$/Unit) of Key Manufacturers (2017-2022)
Table 10. Manufacturers Neuroblastoma Chemotherapy Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Neuroblastoma Chemotherapy Drugs Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Neuroblastoma Chemotherapy Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuroblastoma Chemotherapy Drugs as of 2021)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Neuroblastoma Chemotherapy Drugs Sales by Region (2017-2022) & (K Units)
Table 16. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2022)
Table 17. Global Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 18. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2017-2022)
Table 19. North America Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 20. North America Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2022)
Table 21. North America Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 22. North America Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2022)
Table 23. Europe Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 24. Europe Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2022)
Table 25. Europe Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 26. Europe Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2022)
Table 27. Asia Pacific Neuroblastoma Chemotherapy Drugs Sales by Region (2017-2022) & (K Units)
Table 28. Asia Pacific Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2022)
Table 29. Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue by Region (2017-2022) & (US$ Million)
Table 30. Asia Pacific Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2017-2022)
Table 31. Latin America Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 32. Latin America Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2022)
Table 33. Latin America Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 34. Latin America Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2022)
Table 35. Middle East and Africa Neuroblastoma Chemotherapy Drugs Sales by Country (2017-2022) & (K Units)
Table 36. Middle East and Africa Neuroblastoma Chemotherapy Drugs Sales Market Share by Country (2017-2022)
Table 37. Middle East and Africa Neuroblastoma Chemotherapy Drugs Revenue by Country (2017-2022) & (US$ Million)
Table 38. Middle East and Africa Neuroblastoma Chemotherapy Drugs Revenue Market Share by Country (2017-2022)
Table 39. Global Neuroblastoma Chemotherapy Drugs Sales by Type (2017-2022) & (K Units)
Table 40. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Type (2017-2022)
Table 41. Global Neuroblastoma Chemotherapy Drugs Revenue by Type (2017-2022) & (US$ Million)
Table 42. Global Neuroblastoma Chemotherapy Drugs Revenue Share by Type (2017-2022)
Table 43. Global Neuroblastoma Chemotherapy Drugs Price by Type (2017-2022) & (US$/Unit)
Table 44. Global Neuroblastoma Chemotherapy Drugs Sales (K Units) by Application (2017-2022)
Table 45. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Application (2017-2022)
Table 46. Global Neuroblastoma Chemotherapy Drugs Revenue by Application (2017-2022) & (US$ Million)
Table 47. Global Neuroblastoma Chemotherapy Drugs Revenue Share by Application (2017-2022)
Table 48. Global Neuroblastoma Chemotherapy Drugs Price by Application (2017-2022) & (US$/Unit)
Table 49. Baxter Healthcare Corporation Information
Table 50. Baxter Healthcare Description and Business Overview
Table 51. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 52. Baxter Healthcare Neuroblastoma Chemotherapy Drugs Product
Table 53. Baxter Healthcare Recent Developments/Updates
Table 54. Ingenus Pharmaceuticals Corporation Information
Table 55. Ingenus Pharmaceuticals Description and Business Overview
Table 56. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 57. Ingenus Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product
Table 58. Ingenus Pharmaceuticals Recent Developments/Updates
Table 59. ANI Pharmaceuticals Corporation Information
Table 60. ANI Pharmaceuticals Description and Business Overview
Table 61. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 62. ANI Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product
Table 63. ANI Pharmaceuticals Recent Developments/Updates
Table 64. Teva Pharmaceuticals Corporation Information
Table 65. Teva Pharmaceuticals Description and Business Overview
Table 66. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 67. Teva Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product
Table 68. Teva Pharmaceuticals Recent Developments/Updates
Table 69. Qilu Pharmaceutical Corporation Information
Table 70. Qilu Pharmaceutical Description and Business Overview
Table 71. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 72. Qilu Pharmaceutical Neuroblastoma Chemotherapy Drugs Product
Table 73. Qilu Pharmaceutical Recent Developments/Updates
Table 74. Pfizer Corporation Information
Table 75. Pfizer Description and Business Overview
Table 76. Pfizer Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 77. Pfizer Neuroblastoma Chemotherapy Drugs Product
Table 78. Pfizer Recent Developments/Updates
Table 79. Hikma Pharmaceuticals Corporation Information
Table 80. Hikma Pharmaceuticals Description and Business Overview
Table 81. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 82. Hikma Pharmaceuticals Neuroblastoma Chemotherapy Drugs Product
Table 83. Hikma Pharmaceuticals Recent Developments/Updates
Table 84. Fresenius Kabi Corporation Information
Table 85. Fresenius Kabi Description and Business Overview
Table 86. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 87. Fresenius Kabi Neuroblastoma Chemotherapy Drugs Product
Table 88. Fresenius Kabi Recent Developments/Updates
Table 89. Accord Healthcare Corporation Information
Table 90. Accord Healthcare Description and Business Overview
Table 91. Accord Healthcare Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 92. Accord Healthcare Neuroblastoma Chemotherapy Drugs Product
Table 93. Accord Healthcare Recent Developments/Updates
Table 94. Viatris Corporation Information
Table 95. Viatris Description and Business Overview
Table 96. Viatris Neuroblastoma Chemotherapy Drugs Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 97. Viatris Neuroblastoma Chemotherapy Drugs Product
Table 98. Viatris Recent Developments/Updates
Table 99. Production Base and Market Concentration Rate of Raw Material
Table 100. Key Suppliers of Raw Materials
Table 101. Neuroblastoma Chemotherapy Drugs Distributors List
Table 102. Neuroblastoma Chemotherapy Drugs Customers List
Table 103. Neuroblastoma Chemotherapy Drugs Market Trends
Table 104. Neuroblastoma Chemotherapy Drugs Market Drivers
Table 105. Neuroblastoma Chemotherapy Drugs Market Challenges
Table 106. Neuroblastoma Chemotherapy Drugs Market Restraints
Table 107. Global Neuroblastoma Chemotherapy Drugs Sales Forecast by Type (2023-2028) & (K Units)
Table 108. Global Neuroblastoma Chemotherapy Drugs Sales Market Share Forecast by Type (2023-2028)
Table 109. Global Neuroblastoma Chemotherapy Drugs Revenue Forecast by Type (2023-2028) & (US$ Million)
Table 110. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share Forecast by Type (2023-2028)
Table 111. Global Neuroblastoma Chemotherapy Drugs Sales Forecast by Application (2023-2028) & (K Units)
Table 112. Global Neuroblastoma Chemotherapy Drugs Sales Market Share Forecast by Application (2023-2028)
Table 113. Global Neuroblastoma Chemotherapy Drugs Revenue Forecast by Application (2023-2028) & (US$ Million)
Table 114. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share Forecast by Application (2023-2028)
Table 115. Global Neuroblastoma Chemotherapy Drugs Sales Forecast by Region (2023-2028) & (K Units)
Table 116. Global Neuroblastoma Chemotherapy Drugs Sales Market Share Forecast by Region (2023-2028)
Table 117. Global Neuroblastoma Chemotherapy Drugs Revenue Forecast by Region (2023-2028) & (US$ Million)
Table 118. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share Forecast by Region (2023-2028)
Table 119. Research Programs/Design for This Report
Table 120. Key Data Information from Secondary Sources
Table 121. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Neuroblastoma Chemotherapy Drugs
Figure 2. Global Neuroblastoma Chemotherapy Drugs Market Share by Type in 2021 & 2028
Figure 3. Cyclophosphamide Product Picture
Figure 4. Cisplatin or Carboplatin Product Picture
Figure 5. Vincristine Product Picture
Figure 6. Doxorubicin (Adriamycin) Product Picture
Figure 7. Etoposide Product Picture
Figure 8. Other Product Picture
Figure 9. Global Neuroblastoma Chemotherapy Drugs Market Share by Application in 2021 & 2028
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Other
Figure 13. Global Neuroblastoma Chemotherapy Drugs Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Neuroblastoma Chemotherapy Drugs Market Size (2017-2028) & (US$ Million)
Figure 15. Global Neuroblastoma Chemotherapy Drugs Sales (2017-2028) & (K Units)
Figure 16. Neuroblastoma Chemotherapy Drugs Sales Share by Manufacturers in 2021
Figure 17. Global Neuroblastoma Chemotherapy Drugs Revenue Share by Manufacturers in 2021
Figure 18. The Global 5 and 10 Largest Neuroblastoma Chemotherapy Drugs Players: Market Share by Revenue in 2021
Figure 19. Neuroblastoma Chemotherapy Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
Figure 20. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Region (2017-2022)
Figure 21. Global Neuroblastoma Chemotherapy Drugs Sales Market Share by Region in 2021
Figure 22. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region (2017-2022)
Figure 23. Global Neuroblastoma Chemotherapy Drugs Revenue Market Share by Region in 2021
Figure 24. United States Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 25. Canada Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 26. Germany Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 27. France Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 28. U.K. Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 29. Italy Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 30. Russia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 31. China Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 32. Japan Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 33. South Korea Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 34. India Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 35. Australia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 36. China Taiwan Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 37. Indonesia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 38. Thailand Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 39. Malaysia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 40. Mexico Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 41. Brazil Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 42. Argentina Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 43. Colombia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 44. Turkey Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 45. Saudi Arabia Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 46. UAE Neuroblastoma Chemotherapy Drugs Revenue Growth Rate (2017-2022) & (US$ Million)
Figure 47. Sales Market Share of Neuroblastoma Chemotherapy Drugs by Type (2017-2022)
Figure 48. Manufacturing Cost Structure of Neuroblastoma Chemotherapy Drugs
Figure 49. Manufacturing Process Analysis of Neuroblastoma Chemotherapy Drugs
Figure 50. Neuroblastoma Chemotherapy Drugs Industrial Chain Analysis
Figure 51. Channels of Distribution
Figure 52. Distributors Profiles
Figure 53. Bottom-up and Top-down Approaches for This Report
Figure 54. Data Triangulation
Figure 55. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
